Stryker Corporation
SYKHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeStryker Corporation operates as a medical technology company in the United States and internationally. Valued at $122.63B, SYK is a large-cap name in its sector. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics.
Market Cap
$122.63B
Beta
0.78
P/E (TTM)
38.31
P/E (Fwd)
19.13
EPS (TTM)
$8.35
EPS (Fwd)
$16.72
ROE
15.2%
ROA
7.7%
Cash
$2.96B
Total Debt
$15.23B
Free CF
$4.36B
52W Change
-17.9%
Annual Financials
Cash vs Debt
On the balance sheet, SYK has $2.96B in cash with $15.23B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Annual free cash flow of $4.36B supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 15.2% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 7.7% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $18.45B (2022) to $25.12B (2025), reflecting a 36% increase over the period.
Stryker Corporation carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing SYK.